AR017182A1 - Compuestos de aminotiazol, inhibidores de las kinasas dependientes de ciclinas y las composiciones farmaceuticas que los contienen. - Google Patents

Compuestos de aminotiazol, inhibidores de las kinasas dependientes de ciclinas y las composiciones farmaceuticas que los contienen.

Info

Publication number
AR017182A1
AR017182A1 ARP980105716A ARP980105716A AR017182A1 AR 017182 A1 AR017182 A1 AR 017182A1 AR P980105716 A ARP980105716 A AR P980105716A AR P980105716 A ARP980105716 A AR P980105716A AR 017182 A1 AR017182 A1 AR 017182A1
Authority
AR
Argentina
Prior art keywords
compounds
aryl
alkyl
diseases
pharmaceutical compositions
Prior art date
Application number
ARP980105716A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR017182A1 publication Critical patent/AR017182A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Se revelan compuestos de formula I y a las sales de los mismos aceptables farmacéuticamente. Cuando se utilizan en la formula I, y en toda laespecificacion, los símbolos tienen los siguientes significados: R1 y R2 son independientemente hidrogeno,f luor o alquilo; R3 es arilo o heteroarilo; R4 eshidrogeno, alquilo, cicloalquilo, arilo, cicloalquilalquilo, arilalquilo, heteroarilo, heterocicloalquilalquilo, etc., segun se indica en la descripcion; R5 eshidrogeno o alquilo; m es un numeroentero de 0 a 2; y n es un numero de 1 a 3, teniendo las definiciones precedentes el siguiente alcance: alquilo C1-15,cicloalquilo y arilo: C3-15, heterocicloalquilo y arilo: C3-15 sustituidos por uno a tres heteroátomos elegidos entre el O, S o N.Los comp uestos de la formulaI son inhibidores de la proteína kinasa y son utiles en el tratamiento y prevencion de enfermedades proliferativas, por ejemplo, el cáncer, la inflamacion y laartritis. Los mismos también pueden ser utiles en eltratamiento de enf ermedades neurodegenerativas tales como la enfermedad de Alzheimer, las enfermedadescardiovasculares, las enfermedades virales y las enfermedades fungosas. También se revelan las composiciones farmacéuticas que contienen dichoscompuestos deformula ( I)
ARP980105716A 1997-11-12 1998-11-12 Compuestos de aminotiazol, inhibidores de las kinasas dependientes de ciclinas y las composiciones farmaceuticas que los contienen. AR017182A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6519597P 1997-11-12 1997-11-12

Publications (1)

Publication Number Publication Date
AR017182A1 true AR017182A1 (es) 2001-08-22

Family

ID=22060972

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980105716A AR017182A1 (es) 1997-11-12 1998-11-12 Compuestos de aminotiazol, inhibidores de las kinasas dependientes de ciclinas y las composiciones farmaceuticas que los contienen.

Country Status (32)

Country Link
US (1) US6040321A (es)
EP (1) EP1042307B1 (es)
JP (1) JP4344084B2 (es)
KR (2) KR100454426B1 (es)
CN (1) CN1160343C (es)
AR (1) AR017182A1 (es)
AT (1) ATE374771T1 (es)
AU (1) AU730607B2 (es)
BR (1) BR9814124A (es)
CA (1) CA2309551C (es)
CO (1) CO4990957A1 (es)
CY (1) CY1107509T1 (es)
CZ (1) CZ297907B6 (es)
DE (1) DE69838515T2 (es)
DK (1) DK1042307T3 (es)
EG (1) EG24028A (es)
ES (1) ES2296347T3 (es)
HU (1) HUP0004559A3 (es)
ID (1) ID23983A (es)
IL (1) IL135589A (es)
MY (1) MY120779A (es)
NO (1) NO316773B1 (es)
NZ (1) NZ503828A (es)
PE (1) PE131699A1 (es)
PL (1) PL204642B1 (es)
PT (1) PT1042307E (es)
RU (1) RU2211839C2 (es)
TR (1) TR200001344T2 (es)
TW (1) TW593292B (es)
UY (1) UY25239A1 (es)
WO (1) WO1999024416A1 (es)
ZA (1) ZA9810332B (es)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6414156B2 (en) 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
US6214852B1 (en) * 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6337338B1 (en) * 1998-12-15 2002-01-08 Telik, Inc. Heteroaryl-aryl ureas as IGF-1 receptor antagonists
US20040171632A1 (en) * 1998-12-22 2004-09-02 Gowan Richard Carleton Combination chemotherapy
YU45401A (sh) * 1998-12-22 2004-07-15 Warner-Lambert Company Antikancerogena kombinacija
EP1172359A4 (en) * 1999-04-07 2002-09-11 Santen Pharmaceutical Co Ltd N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE, AND ITS USE AS AN INHIBITOR OF TNF PRODUCTION- $ g (a)
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
IL144910A0 (en) 1999-04-15 2002-06-30 Bristol Myers Squibb Co Cyclic compounds and pharmaceutical compositions containing the same
UA71971C2 (en) * 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
ES2251395T3 (es) 1999-07-26 2006-05-01 Banyu Pharmaceutical Co., Ltd. Derivados de biarilureas.
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
US6392053B2 (en) 1999-12-15 2002-05-21 Bristol-Myers Squibb Company Process for preparing arylacetylaminothiazoles
US6515004B1 (en) 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
MY125768A (en) * 1999-12-15 2006-08-30 Bristol Myers Squibb Co N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
AU2001230026A1 (en) * 2000-02-04 2001-08-14 Novo-Nordisk A/S 2,4-diaminothiazole derivatives
IT1317826B1 (it) * 2000-02-11 2003-07-15 Dompe Spa Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8.
EP1274706A1 (en) 2000-04-18 2003-01-15 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinases
US6534531B2 (en) * 2000-04-27 2003-03-18 Bristol-Myers Squibb Company Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
WO2001095856A2 (en) * 2000-06-15 2001-12-20 Chaconne Nsi Co., Ltd. Urea derivative useful as an anti-cancer agent and process for preparing same
YU4903A (sh) * 2000-07-26 2006-03-03 Bristol-Myers Squibb Company N-/5-///5-alkil-2-oksazolil/metil/tio/-2-tiazolil/ karboksamidni inhibitori ciklin zavisnih kinaza
MXPA03001189A (es) * 2000-08-09 2004-05-14 Agouron Pharma Compuestos de pirazol-tiazol, composiciones farmaceuticas que los contienen y su uso para inhibir las cinasas dependientes de ciclinas.
US20020173507A1 (en) * 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
ATE318812T1 (de) * 2000-12-21 2006-03-15 Bristol Myers Squibb Co Thiazolyl-inhibitoren von tyrosinkinasen der tec- familie
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
HU229349B1 (en) 2001-01-25 2013-11-28 Bristol Myers Squibb Co Methods for preparation of pharmaceutical composition containing epothilone analogs useful for treatment of cancer
ES2318001T3 (es) * 2001-03-19 2009-05-01 Novartis Ag Combinaciones que comprenden un agente antidiarreico y una epotilona o un derivado de epotilona.
ES2254611T3 (es) 2001-05-11 2006-06-16 Pfizer Products Inc. Derivados de tiazol.
EP1721609A3 (en) * 2001-05-16 2007-01-31 GPC Biotech AG Pyridylpyrimidine derivatives as effective compounds against prion diseases
ATE445400T1 (de) 2001-05-25 2009-10-15 Bristol Myers Squibb Co Hydantion-derivate als hemmer von matrix- metalloproteinasen
HN2002000156A (es) 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
IL159570A0 (en) * 2001-07-19 2004-06-01 Pharmacia Italia Spa Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
PL368035A1 (en) * 2001-08-31 2005-03-21 Bristol-Myers Squibb Company Compositions and methods for the treatment of cancer
US7405234B2 (en) * 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
EP1531815B1 (en) 2002-06-27 2014-09-24 Novo Nordisk A/S Glucokinase activators
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
ES2285164T3 (es) * 2002-09-04 2007-11-16 Schering Corporation Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina.
US7161003B1 (en) * 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
DE60313872T2 (de) * 2002-09-04 2008-01-17 Schering Corp. Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
US7205308B2 (en) * 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
JP2006500391A (ja) * 2002-09-04 2006-01-05 シェーリング　コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
ATE376548T1 (de) * 2002-09-04 2007-11-15 Schering Corp Pyrazolopyrimidine als hemmstoffe cyclin- abhängiger kinasen
NZ539013A (en) * 2002-10-03 2007-05-31 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
SI1549638T1 (sl) 2002-10-03 2008-02-29 Hoffmann La Roche Indol-3-karboksiamidi kot aktivatorji glukokinaze(gk)
BR0315580A (pt) * 2002-10-24 2005-08-30 Merck Patent Gmbh Derivados de metileno uréia
EP1567487A4 (en) * 2002-11-15 2005-11-16 Bristol Myers Squibb Co OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
CA2533803A1 (en) * 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
US6949895B2 (en) * 2003-09-03 2005-09-27 Axcelis Technologies, Inc. Unipolar electrostatic quadrupole lens and switching methods for charged beam transport
US7256208B2 (en) * 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
PT1723128E (pt) 2004-01-06 2013-02-27 Novo Nordisk As Heteroaril-ureias e o seu uso como activadores da glicoquinase
WO2005072731A1 (en) * 2004-01-29 2005-08-11 X-Ceptor Therapeutics, Inc. 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
CN1938279B (zh) 2004-01-30 2011-09-14 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白调控剂
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US20050182105A1 (en) * 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
US7820702B2 (en) * 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
EP1568368A1 (en) * 2004-02-26 2005-08-31 Schering Aktiengesellschaft Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7388027B2 (en) * 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7211576B2 (en) 2004-04-20 2007-05-01 Hoffmann-La Roche Inc. Diaminothiazoles
KR20070084325A (ko) 2004-11-18 2007-08-24 브리스톨-마이어스 스큅 컴퍼니 익사베필론을 포함하는 장용성 코팅된 비드 및 그의 제조방법
US20100105745A1 (en) * 2005-01-04 2010-04-29 Toshinari Minamoto Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta
WO2006073202A1 (ja) * 2005-01-04 2006-07-13 National University Corporation Kanazawa University GSK3β阻害効果に基づくがんの抑制および抗がん剤の評価方法
US7999114B2 (en) 2005-07-08 2011-08-16 Novo Nordisk A/S Dicycloalkylcarbamoyl ureas as glucokinase activators
US7884210B2 (en) * 2005-07-14 2011-02-08 Novo Nordisk A/S Ureido-thiazole glucokinase activators
CN101365700A (zh) * 2005-11-15 2009-02-11 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氮杂吲唑
US7592461B2 (en) * 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7888504B2 (en) * 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
US20080188524A1 (en) * 2006-10-25 2008-08-07 Martin Augustin Methods of treating pain
CA2671492A1 (en) 2006-12-04 2008-06-12 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with cupredoxins and cpg rich dna
EP2519517B1 (en) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
SG185414A1 (en) 2010-05-12 2012-12-28 Univ Vanderbilt Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
ES2685171T3 (es) 2010-06-14 2018-10-05 The Scripps Research Institute Reprogramación de células a un nuevo destino
EP2635124A4 (en) * 2010-11-01 2014-04-16 Romark Lab Lc ALKYLSULFINYL-SUBSTITUTED THIAZOLIDE COMPOUNDS
EP2665493B1 (en) 2011-01-20 2018-03-21 Board Of Regents, The University Of Texas System Mri markers, delivery and extraction systems, and methods of manufacture and use thereof
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
US8940742B2 (en) * 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2014075391A1 (zh) 2012-11-17 2014-05-22 北京市丰硕维康技术开发有限责任公司 离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
WO2014151953A1 (en) 2013-03-15 2014-09-25 The California Institute For Biomedical Research Compounds and methods for inducing chondrogenesis
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EA201690713A1 (ru) 2013-10-04 2016-08-31 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
DK3119397T3 (da) 2014-03-19 2022-03-28 Infinity Pharmaceuticals Inc Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
JP6861166B2 (ja) 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
JP7028766B2 (ja) * 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
AU2016322552B2 (en) 2015-09-14 2021-03-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
PE20181804A1 (es) * 2016-04-06 2018-11-19 Innovative Molecules Gmbh Derivados de aminotiazol utiles como agentes antiviricos
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2016426574B2 (en) 2016-10-11 2023-07-13 Euro-Celtique S.A. Hodgkin lymphoma therapy
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
AR113344A1 (es) * 2017-10-05 2020-04-22 Innovative Molecules Gmbh Enantiómeros de una serie de compuestos antivirales
CA3093025A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
EP4229037A2 (en) * 2020-10-16 2023-08-23 CeMM - Forschungszentrum für Molekulare Medizin GmbH Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1088049A (en) * 1975-06-03 1980-10-21 Takashi Masugi 3-substituted-7-substituted alkanamido-3-cephem-4- carboxylic acid compounds and processes for preparation thereof
NO831160L (no) * 1982-04-08 1983-10-10 Erba Farmitalia Fremstilling av substituerte penem-derivater
JPS6339868A (ja) * 1986-08-04 1988-02-20 Otsuka Pharmaceut Factory Inc ジ低級アルキルフエノ−ル誘導体
DE4119756A1 (de) * 1991-06-15 1992-12-17 Basf Ag Aminoalkylsubstituierte 5-mercaptothiazole, ihre herstellung und verwendung
JPH0859669A (ja) * 1994-06-13 1996-03-05 Takeda Chem Ind Ltd セフェム化合物、その製造法及び剤

Also Published As

Publication number Publication date
DE69838515T2 (de) 2008-07-03
WO1999024416A1 (en) 1999-05-20
DK1042307T3 (da) 2008-01-28
DE69838515D1 (de) 2007-11-15
NZ503828A (en) 2003-03-28
NO316773B1 (no) 2004-05-03
IL135589A0 (en) 2001-05-20
PL340540A1 (en) 2001-02-12
PE131699A1 (es) 2000-03-08
RU2211839C2 (ru) 2003-09-10
ID23983A (id) 2000-06-14
ATE374771T1 (de) 2007-10-15
EP1042307A1 (en) 2000-10-11
BR9814124A (pt) 2000-10-03
EG24028A (en) 2008-03-26
CA2309551C (en) 2006-03-28
JP2001522842A (ja) 2001-11-20
IL135589A (en) 2004-06-20
ES2296347T3 (es) 2008-04-16
CO4990957A1 (es) 2000-12-26
ZA9810332B (en) 2000-05-11
CZ20001744A3 (en) 2001-05-16
CN1160343C (zh) 2004-08-04
AU730607B2 (en) 2001-03-08
CY1107509T1 (el) 2013-03-13
TR200001344T2 (tr) 2000-09-21
CN1278806A (zh) 2001-01-03
CA2309551A1 (en) 1999-05-20
PT1042307E (pt) 2007-11-15
PL204642B1 (pl) 2010-01-29
AU1295599A (en) 1999-05-31
HUP0004559A3 (en) 2002-05-28
CZ297907B6 (cs) 2007-04-25
NO20002153D0 (no) 2000-04-27
KR20010031896A (ko) 2001-04-16
US6040321A (en) 2000-03-21
NO20002153L (no) 2000-05-11
EP1042307A4 (en) 2003-01-29
UY25239A1 (es) 2000-12-29
EP1042307B1 (en) 2007-10-03
TW593292B (en) 2004-06-21
KR20030036862A (ko) 2003-05-09
KR100454426B1 (ko) 2004-10-26
HUP0004559A1 (hu) 2002-04-29
MY120779A (en) 2005-11-30
JP4344084B2 (ja) 2009-10-14

Similar Documents

Publication Publication Date Title
AR017182A1 (es) Compuestos de aminotiazol, inhibidores de las kinasas dependientes de ciclinas y las composiciones farmaceuticas que los contienen.
UY27592A1 (es) Nuevo uso
HUP0202703A2 (hu) Poli(ADP-ribóz) polimerázok triciklusos inhibítorai és ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
AR017852A1 (es) COMPUESTOS DE PIRAZOLO (3,4-b)PIRIDINA Y SUS SALES, UTILES COMO INHIBIDORES DE LAS PROTEINA-QUINASAS DEPENDIENTES DE CICLINA, Y LAS COMPOSICIONESFARMACEUTICAS QUE LOS CONTIENEN, EVENTUALMENTE ASOCIADOS CON UN AGENTE ANTICANCER.
SE0104340D0 (sv) New compounds
HRP20050830A2 (en) Non-nucleoside reverse transcriptase inhibitors i for treating hiv mediated diseases
AR030563A1 (es) N-[5-[[[5-alquil-2-oxazolil]metil]tio]-2-tiazolil]carboxamidas inhibidoras de cinasas dependientes de la ciclina y composiciones farmaceuticas que las contienen
ATE495155T1 (de) Heterocyclische inhibitoren von mek
CO4900068A1 (es) Piperazina di - n - sustituidas y piperidinas 1,4 -di- sustituidas utiles como antagonistas muscarinicos
ECSP045229A (es) Piridinonas sustituidas como moduladores de la p38 map quinasa
AR032136A1 (es) Compuestos espiroheterociclicos utiles como inhibidores reversibles de cisteina-proteasas
ES2081187T3 (es) Nuevas naftil-alquil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
ES2123039T3 (es) Nuevas 3-(hidroxi-bencilidenil)-indolin-2-onas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
BR0314393A (pt) Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia
DE60226729D1 (de) Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
ATE335748T1 (de) Thienopyrimidindione und deren verwendung bei der modulierung von autoimmunerkrankungen
AR037772A1 (es) Formas de sal e-2-metoxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino]quinazolin-6-il]alil)acetamida y procedimiento de produccion
PA8432901A1 (es) Compuestos de piridilpirrol
BR0010716A (pt) Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas
ES2179353T3 (es) Antagonistas muscarinicos.
NZ307505A (en) Arylglycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds
SE0301446D0 (sv) New Compounds
AR006360A1 (es) Derivados de 1,2,3,4-tetrahidronaftaleno substituidos, uso de los mismos para la preparacion de medicamentos y procedimiento para su preparacion.
AR026974A1 (es) N-[5-[[[5-alquil-2-oxazolil]metil]tio]-2-tiazolil]-carboxamidas, utiles como inhibidores de cinasas dependientes de ciclina, y las composicionesfarmaceuticas que los contienen

Legal Events

Date Code Title Description
FB Suspension of granting procedure